voxelotor sickle
Selected indexed studies
- Sickle Cell Disease: A Review. (JAMA, 2022) [PMID:35788790]
- A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease. (N Engl J Med, 2019) [PMID:31199090]
- Voxelotor: A Novel Treatment for Sickle Cell Disease. (Ann Pharmacother, 2021) [PMID:32674605]
_Worker-drafted node — pending editorial review._
Connections
voxelotor sickle is a side effect of
Sources
- Sickle Cell Disease: A Review. (2022) pubmed
- Advances in the diagnosis and treatment of sickle cell disease. (2022) pubmed
- A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease. (2019) pubmed
- Voxelotor: A Novel Treatment for Sickle Cell Disease. (2021) pubmed
- Voxelotor for the treatment of sickle cell disease in pediatric patients. (2022) pubmed
- Voxelotor for the treatment of sickle cell disease. (2021) pubmed
- Voxelotor: alteration of sickle cell disease pathophysiology by a first-in-class polymerization inhibitor. (2021) pubmed
- Voxelotor: A Ray of Hope for Sickle Disease. (2020) pubmed
- The vaso-occlusive pain crisis in sickle cell disease: Definition, pathophysiology, and management. (2020) pubmed
- Systematic Review of Voxelotor: A First-in-Class Sickle Hemoglobin Polymerization Inhibitor for Management of Sickle Cell Disease. (2020) pubmed